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Abstract. Influenza is a highly contagious, major respiratory tract 
disease affecting millions of people each year. At present, two 
classes of antivirals are available: the neuraminidase inhibitors and 
the M2 proton channel blockers amantadine and rimantadine. 
However, rapid emergence of M2 blockers resistance makes 
imperative the development of new anti-influenza drugs. In the last 
few years several groups have synthesized and evaluated several 
analogs of amantadine. While several of them are active against 
wild-type M2 channel only a few are able to inhibit the mutant ion 
channels that lead to amantadine-resistance.  
 
Introduction 
 
 Influenza is a worldwide epidemic that causes substantial morbidity and 
mortality. Of the three types of influenza viruses, A, B and C, influenza A and B  
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cause seasonal epidemics. Moreover, influenza A viruses are responsible for 
sporadic pandemics that usually cause higher mortality rates than seasonal 
influenza epidemics. The most severe pandemic, the “Spanish flu”, occurred 
in 1918, is thought to have killed more individuals than any disease outbreak 
in history, resulting in approximately 40 million deaths worldwide [1]. More 
recent pandemics in 1957 (“Asian flu”, H2N2 strain) and 1968 (“Hong Kong 
flu”, H3N2 strain) were not as deadly, yet influenza remains a grave health 
hazard [2]. For example, in the United States, according to the Center for 
Disease Control and Prevention (CDC), influenza and its complications are 
currently the leading cause of death due to any infectious disease. In fact, in 
2009, a new influenza virus (“swine flu”, H1N1 strain) originated a new 
pandemic that caused much concern, although, thankfully, was not as deadly 
as initially thought [3]. In addition, H5N1 viruses (“bird flu”), which are also 
currently worldwide circulating, are extremely virulent in humans but have 
not acquired the ability for efficient human-to-human transmission yet [4]. 
 Influenza A viruses infect a wide range of avian and mammalian hosts, 
unlike influenza B viruses, which infect only humans. Influenza A and B 
viruses are enveloped negative-strand segmented RNA viruses. The envelope 
of influenza A viruses contains two different surface glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA) [5]. Influenza A viruses are 
categorized into antigenic HA and NA subtypes: 16 HA (H1–H16) and 9 NA 
(N1–N9) antigenic subtypes have been identified so far. For example, the 
2009 “swine flu” is an H1N1 virus because it contains a H1 subtype HA and a 
N1 subtype NA. 
 The major influenza A subtypes that have infected humans during 
seasonal epidemics are H1N1, H2N2 and H3N2. Within a subtype, different 
strains arise as a result of point mutations in a process known as ‘genetic 
drift’. These new strains cause seasonal epidemics. A new pandemic can 
emergence by two different mechanisms: by direct transmission from animals, 
usually birds, to humans, as happened in 1918 with the “Spanish flu”; or 
through reassortment of an avian influenza virus with a human influenza 
virus, as occurred in 1957 with the “Asian flu” (H2N2) and, again, in 1968 
with the “Hong Kong flu” (H3N2) [6]. The H1N1 virus of the 2009 “swine 
flu” is an apparent reassortment of four endemic strains of influenza: one from 
humans, one from birds, and two from pigs, a fact that further exemplifies the 
versatility of the influenza A virus [3]. When a new pandemic starts, the HA 
of the new strain differs substantially from recent HAs of seasonal influenza A 
viruses and, consequently, most of the human population lacks immunological 
protection against this virus, resulting in a pandemic. 
 There are two different strategies for combating influenza: vaccination 
and chemotherapy. The primary defense against influenza A has been 
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vaccination with inactivated or live-attenuated virus. However, vaccination 
effectiveness is limited due to the antigenic drifts and shifts that the 
influenza virus undergoes from year to year, and new influenza vaccines 
must be designed every year by predicting the genetic drift of seasonal 
influenza A. Antivirals have also been used for both prophylactic and 
therapeutic treatments during seasonal epidemics [5b]. Additionally, 
antivirals are particularly important at the beginning of a fast-spreading 
pandemic because the timely production of sufficient amounts of an 
effective vaccine is difficult. Current antivirals are directed against the M2 
ion-channel protein of the influenza A virus (amantadine and rimantadine, 
Fig. 1) and the NA of the influenza A and B virus (zanamivir and 
oseltamivir) [8]. However, many influenza virus strains have developed 
resistance to adamantanes and/or oseltamivir (the only orally bioavailable 
NA inhibitor), highlighting a major health risk [9]. For example, after four 
decades of effective use of amantadine, resistance by influenza viruses of 
the A/H3N2 subtype currently exceeds 90% in the United States, and virus 
mutants are as fit as the wild-type (wt) virus. The situation is even worst 
with the new 2009 pandemic H1N1 influenza. In both strains, the basis for 
resistance is a single Ser to Asn amino acid replacement (S31N) in the 
matrix M2 ion channel, which interferes with the drug's ability to block M2 
ion channel activity and viral replication [10]. 
 
 
 
Figure 1. The structures of the anti-influenza A drugs amantadine and rimantadine. 
 
 Another important problem encountered in the administration of 
amantadine and rimantadine is related to the central nervous system side 
effects of both drugs. In fact, amantadine has been used in the treatment of 
Parkinson’s disease, although its antiparkinsonian effect is poorly understood 
[11]. The side effects of rimantadine are analogous, but somewhat less 
pronunced than those of amantadine [12]. 
 The appearance of pandemic H1N1 and highly pathogenic avian influenza 
viruses of the H5N1 subtype being able to infect humans, the emergence of 
resistances, and the side effects of amantadine and rimantadine reveal the 
urgent need for the development of new antiviral drugs [13]. 
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 In this review, we will focus on the design of new amantadine analogs 
targeting the matrix M2 ion channel of influenza A virus. 
 
1. The M2 protein 
 
 The influenza A virus M2 protein is a homotetrameric protein containing 
four parts: a short unstructured N-terminal extracellular domain, important for 
incorporation into the virion; a transmembrane helix that is necessary for 
tetramerization, proton conductance and drug-binding; a cytoplasmic 
amphiphilic helix, involved in cholesterol-binding, membrane localization, 
budding and scission; and a disordered tail that interacts with the matrix 
protein M1 [14]. 
 The influenza virus enters its target cells by receptor-mediated 
endocytosis, which is followed by acid-induced fusion of the viral and 
endosomal membranes. This fusion event is mediated by a conformational 
change of the influenza HA proteins, triggered by the low pH in the endosome 
lumen [15]. The transmembrane region of the M2 protein forms a pH-
activated channel that selectively conducts protons along a chain of water 
molecules and ionizable sidechains, including His37, playing an essential role 
for viral replication equilibrating the pH of the virus interior with that of the 
acidic endosome. When the endosome is acidified, His37 residues in the 
transmembrane region of M2 become protonated, leading to the opening of 
the M2 channel and to a proton influx from the endosome into the virus 
interior [16]. The acidification of the virus interior enables the release of the 
viral RNA into the host’s cytoplasm after membrane fusion has taken place. In 
addition, it has been shown that, for some strains of influenza A virus, the M2 
proton channel function is required for preventing a premature HA 
conformation transition when newly synthesized viral proteins are trafficked 
through the trans-Golgi network [17]. 
 The replication of the influenza A virus can be stopped by inhibiting the 
activity of the M2 channel, using amantadine and rimantadine. 
 Although the role of the M2 protein as the target for amantadine and 
rimantadine has been known for more than twenty years [18], only very recent 
functional, structural [19] and computational [20] studies have revealed that 
the drugs inhibit proton conduction by binding to an aqueous cavity adjacent 
to M2’s proton-selective filter, thereby blocking access of proton to the filter 
[14]. These recent works enable novel insights into the adamantanes-
resistance and provide a solid basis for structure-based drug design. 
 The number of drug-resistant variants of influenza A M2 channel is 
limited by the very conserved nature of the binding site within the channel. 
Thus, only a few amantadine-resistant mutations, namely V27A, L26F and 
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S31N, have been widely observed in transmissible strains of the virus in the 
past eight decades for which a genetic record is available [21], although other 
mutations can easily be observed in vitro [22]. The mutations that cause the 
greatest decrease in inhibition, S31N and V27A, increase the polarity of pore-
lining residues. 
 
2. 1-Substituted-adamantanes 
 
 Amantadine and rimantadine exhibit their inhibitory activity at 
micromolar concentrations. Rimantadine has a superior intrinsic antiviral 
activity compared to amantadine, but peak plasma levels of rimantadine are    
2-3 fold lower than those achieved with amantadine when given at the same 
dose [23]. Amantadine was initially licensed in USA in 1966. Interestingly, 
for many years, amantadine was mainly used in western countries, while 
rimantadine was used in the former USSR and eastern European countries 
[24]. 
 Both drugs are rather old, therefore it is not a great surprise that 
hundreds of derivatives have been synthesized and pharmacologically 
tested. In fact, soon after the publication of the antiviral activivity of 
amantadine by du Pont de Nemours’ researchers [25], several amantadine 
derivatives were synthesized and evaluated as anti-influenza agents [26]. 
Most of these analogs were alkylaminoalkyl derivatives of adamantane (Fig. 2), 
although some derivatives featuring aditional polar groups, such as alcohols, 
amines, ethers, or derivatives lacking an amino group were also synthesized 
and tested (Fig. 3). 
 
 
 
Figure 2. Alkylamantadines and related compounds. 
 
 
 
Figure 3. Amantadine analogs featuring polar groups. 
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 Although several of these compounds displayed anti-viral activities 
similar to that of amantadine, they showed cross-resistance with amantadine 
and rimantadine, so their therapeutical interest is rather low. 
 Worthy of note, while amantadine is, for the most part, excreted without 
metabolism [27], rimantadine is extensively metabolized by hydroxylation 
before excretion in the urine [23c,28]. Manchand and coworkers reported 
the synthesis of three hydroxylated metabolites of rimantadine and showed 
that 2-hydroxyrimantadine was as active against several influenza A virus       
as amantadine, while the 3- and the 4-hydroxy derivatives showed                    
only very modest inhibitory activity (Fig. 4). Unfortunately, rimantadine-
resistant strains exhibited cross-resistance to the 2-hydroxyamantadine                 
[29]. 
 
rimantadine
NH2
3-hydroxyrimantadine
NH2
HO
2-hydroxyrimantadine
NH2
OH
4-hydroxyrimantadine
NH2HO
 
 
Figure 4. Rimantadine and its hydroxylated metabolites. 
 
 The antiviral activity of 2-hydroxyrimantadine was the first example of a 
trend that has also been observed in much more recent work using amantadine 
and other polycyclic systems, that is, the introduction of polar groups in the 
polycyclic scaffold is tolerated, but does not enhance the potency of 
amantadine and related aminopolycyclic derivatives. For example, in 2011, 
Wang et al. described that the aminoalcohol 3 showed an IC50 = 16 μM 
against the wt M2 channel from influenza A virus, exactly the same value than 
that reported for amantadine [30]. Surprisingly, they found that                     
1-adamantanol, 1, and 2-methyl-2-adamantanol, 2, showed IC50 values very 
close to that of amantadine, while the 3-amino-1-adamantanol, 4, showed to 
be inactive (Fig. 5). 
 
 
 
Figure 5. Several hydroxylated analogs of amantadine. IC50 values (against wt M2 
channel): amantadine (16 μM), 1 (20 μM), 2 (14 μM), 3 (16 μM), 4 (not active). 
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 Kolocouris’ group has reported the synthesis and anti-influenza activity of a 
series of heterocyclic rimantadine analogs (Fig. 6) [31]. The aziridine and the 
azepine derivatives were much less active than amantadine, while azetidine 6 
(R1=H), pirrolidines 7a (R1=R2=H) and 7b (R1=H, R2=CH3), and piperidine 8 
(R1=H) showed to be more potent than amantadine and rimantadine against the 
influenza A2/Japan/305/57 (H2N2) strain. Compounds 6 and 7b also showed 
good inhibitory activity against the influenza A/Hong Kong/68 (H3N2) strain. 
While amantadine displayed IC50 of 42 and 6 μM against A2/Japan/305/57 and 
A/Hong Kong/68, respectively, the most potent compound within this series, 7b, 
showed IC50 of 1.6 and 1.8 μM against A2/Japan/305/57 and A/Hong Kong/68, 
respectively. The introduction of an additional alkyl group in the nitrogen atom 
caused a dramatic reduction in anti-influenza activity. 
 
 
 
Figure 6. Heterocyclic rimantadine analogs. 
 
 Later on, the same group reported analogs of rimantadine featuring a 
second nitrogen atom, the aim of this modification being the incorporation of 
additional hydrogen bonding interactions with the M2 protein [32]. Although 
the presence of this second amino group was compatible with anti-influenza 
activity, the new analogs were not more potent than rimantadine. Thus, 
compounds 10 and 11 (Fig. 7) displayed EC50 of 18.3 and 24.1 μM, 
respectively, against A/Hong Kong/68 (H3N2) strain, very similar values to 
that of rimantadine (EC50 = 19.1 μM). 
 
 
 
Figure 7. Rimantadine analogs featuring a second nitrogen atom. 
 
 As previously stated, amantadine interferes with the ion channel function of 
the M2 protein of influenza A virus at low micromolar concentrations. 
Interestingly, a second mechanism of action of amantadine, at least in some 
influenza A strains, is on the hemagglutinin, at concentrations around 100 times 
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higher. Theoretically, an amantadine derivative able to simultaneously interact 
with both targets at the same concentrations should have a reduced probability 
to develop resistance. In this case, two mutations, one in each target protein 
would be necessary at once. With this aim, Scholtissek and coworkers reported 
the synthesis and evaluation of forty adamantane derivatives and tested them 
against the influenza A/Singapore/1/57 (H2N2) strain [33]. They found several 
analogs active against this strain and also against A/Swine/1976/31 and 
A/Udorn/307/72, although all the products were inactive against A/WSN/33, 
which is amantadine-resistant. Most of the active compounds at low micromolar 
concentrations (e. g., 12-14) interacted with the M2 protein; the corresponding 
escape mutants produced with them had amino acid replacements at positions 
27, 30 or 31 of the M2 protein. Interestingly, they found two compounds, 15 and 
16 (Fig. 8), able to interact with both the ion channel and the hemagglutinin at 
about the same concentration. It was expected that in order to become resistant 
the virus should mutate both proteins. However, the resistant mutants to these 
compounds showed mutations only in the HA protein [33].  
 
 
 
Figure 8. Some of the amantadine analogs reported by Scholtissek and coworkers. 
 
 Very recently, Zarubaev and coworkers have reported the synthesis and 
the anti-influenza activity of a series of di-, tri- and tetrazole derivatives of 
amantadine. Interestingly, several compounds were active against the 
amantadine-resistant influenza A/Puerto Rico/8/34 strain, which bears the 
S31N mutation in its M2 channel. Tetrazoles such as 17, 18 and 19 (Fig. 9), 
showed micromolar values of EC50 and higher selectivity index (SI) than 
rimantadine [34]. It remains to be clarified if the target of these adamantane 
derivatives is the M2 channel of the influenza virus. 
 
 
 
Figure 9. Tetrazolo-adamantanes with anti-influenza A virus activity. 
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 Finally, Zhang et al., have reported that an L-histidine derivative of 
adamantane, 20 (Fig. 10), was able to inhibit the wt, the S31N, and the double 
mutant S31N/L26I M2 channels of avian H5N1 influenza expressed in cell 
lines of transformed HEK 293. The IC50 of 20 against the wt, the S31N mutant 
and the double mutant S31N/L26I channels were 5.84, 10.96 and 9.77 μM, 
respectively [35]. However, these data were not confirmed with viral 
inhibition assays. 
 
 
 
Figure 10. Structure of histidine derivative 20. 
 
3. 2-Substituted-adamantanes 
 
 2-Amantadine is only moderately active against influenza virus. The anti-
viral activity improved by the incorporation of a 2-ethyl or 2-n-propyl group, 
although the introduction of a methyl group in C-2 diminished the activity. 
Interestingly, 2-methyl-2-adamantanol, 2a, showed an EC50 of 3 μM against 
influenza A/Japan/305/57 (H2N2) strain, very similar to the EC50 of 
amantadine against this strain (1.1 μM) [36]. As previously stated, 2a inhibits 
the wt M2 channel of influenza A with an IC50 of 14 μM [30]. In 2010, 
Kolocouris’ group reported that several adamantanaminoalcohols such as 23 
and 24 (Fig. 11) had potent anti-influenza activity. For example, aminoalcohol 
23, displayed submicromolar activity against the influenza A /Hong 
Kong/7/87 (H3N2) strain [37].  
 
21a-c
R
NH2
2a-c
R
OH
22
NH2
OH
23
NH2
OH
 
   
Figure 11. 2,2-Disubstituted adamantanes. a, R = methyl; b, R = ethyl; c, R = n-propyl. 
 
 Although 2-amantadine is only moderately active against influenza virus, 
the 2-isomer of rimantadine, 24 (Fig. 12), was found to be 4 times more potent 
than rimantadine against the influenza A2/Japan/305/57 (H2N2) strain. This 
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finding led to Kolocouris’ and De Clercq’s groups to investigate the antiviral 
activity of several 2-alkyl and 2-cycloalkyl analogs of rimantadine [38]. They 
found that alkylation of the nitrogen atom reduced the anti-viral activity as did 
the introduction of a methyl group in the C-2 of the adamantane, as in 25. 
Unfortunately, 24 was much less potent against X-31, a reassortant influenza 
A H3N2 strain (A/Hong Kong/1/68 with A/Puerto Rico/8/34) carrying the 
S31N mutation. 
 They also investigated the activity of 2-(2-adamantyl)piperidines, 2-(2-
adamantylmethyl)piperidines and 3-(2-adamantyl)pyrrolidines. In these series 
they found that while the alkylation of the nitrogen atom reduced the activity, 
as in going from 26a to 26b, the introduction of a further nitrogen atom two 
carbon away from the heterocyclic ring, as in 27a-c or 28 led to high anti-viral 
potency. For example, compounds 27a-c showed EC50 between 3 and 7 μM, 
against the X-31 strain, much lower than amantadine (EC50 = 49 μM) or 
rimantadine (EC50 = 19 μM). Taking into account the size of the diamines, it 
seems like the M2 receptor site can accommodate cages much larger than the 
adamantane. Unfortunately, the selectivity index (SI) of these compounds was 
much lower than that of amantadine or rimantadine [39]. 
 
 
 
Figure 12. 2-Substituted analogs of rimantadine. 
 
4. Azaspiroadamantanes 
 
 A unique kind of 2-substituted adamantanes is the group of the 
azaspiroadamantanes, because several of these derivatives have very potent 
anti-influenza activity. 
 Forty years ago, researchers at N. V. Philips-Duphar synthesized a series of 
azaspiroadamantanes (Fig. 13) [40]. Several of these amantadine analogs 
showed anti-influenza activity and, in fact, one of them, DU 34796, that had an 
antiviral spectrum in vitro wider than that of amantadine and was more potent 
than amantadine against mouse influenza, entered clinical trials, although finally 
the drug was not further developed [41]. The main problem of these compounds 
was, once again, the cross-resistance with amantadine and rimantadine. 
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Figure 13. Spiro adamantane derivatives synthesized by N. V. Philips-Duphar. R is a 
lower alkyl group. 
 
 As 2-adamantanamine is only moderately active against influenza virus, 
the antiviral activity of the aforementioned derivatives points out that a carbon 
substituent in the vicinity of the 2-adamantyl carbon leads to a remarkable 
increase in antiviral activity. We will see further examples of this behaviour in 
the following paragraphs and also in different analogs that will be shown in 
the next sections. 
 In the nineties, Kolocouris’ group, successfully revisited the topic, 
synthesizing several azaspiro- and oxazaspiro-adamantanes, such as those 
shown in Fig. 14. The compounds were examined against several influenza A 
strains (H1N1, H2N2 and H3N2) by De Clercq’s group. Interestingly, against 
a H2N2 strain, the compound 32b was found to be up to 230 times more 
active than amantadine. Although 32b showed a SI of 714 in vitro, 
unfortunately, it proved rather toxic in vivo. Worthy of note, the change of a 
methylene unit by an oxygen atom was compatible with anti-influenza 
activity, although these oxa-analogs were less active than amantadine [42]. 
 
 
 
Figure 14. Azaspiro- and oxazaspiro-adamantane derivatives. a, R = H; b, R = methyl; 
c, R = ethyl; d, R = cyclopropylmethyl. 
 
 Later on, with the aim of improving the antiviral activity, Kolocouris’s 
group explored the introduction of a methyl group in the pyrrolidine ring of 
32a and 32b (Fig. 15). While the introduction of a methyl in either C-3 or C-4 
of the pyrrolidine ring of 32a and 32b led to slightly less active compounds, 
introduction of a methyl in C-5 of the pyrrolidine was optimal for biological 
activity against H2N2 strain. Unfortunately, all pyrrolidines had lower SI than 
amantadine [43]. 
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Figure 15. C-methyl derivatives of azaspiroadamantanes 32a-b. a, R = H; b, R = methyl. 
 
 More recently, Kolocouris et al. have completed this series with the 
synthesis of ring-contracted and ring-expanded analogs of 32a (Fig. 16) [44]. 
Azaspiro derivatives 38-41 were synthesized and tested against an H3N2 
strain of influenza A. Whereas aziridine derivatives 38a,b were less potent 
than amantadine, azetidines 39a,b and 40, and the piperidine derivatives 41a,b 
were more potent than amantadine. Piperidine 41a, the most potent of them, 
showed significant anti-influenza A virus activity, being 12-fold more active 
than amantadine and about 2-fold more active than rimantadine. Azetidine 
36a, while being slightly less potent than 41a showed a better SI (694 vs 106). 
Methyl substitution at the nitrogen atom of all heterocycles caused reduction 
in anti-influenza virus A potency. 
 
 
 
Figure 16. Ring-contracted and ring-expanded analogs of 32. a, R = H; b, R = methyl. 
 
 Very recently, Kolocouris’ group has reported the synthesis of several 
spiropiperazines of general structure 42 (Figure 17) [45]. These compounds 
can be regarded as analogs of 33 and 34 featuring an additional nitrogen atom. 
The main aim of this approach was to introduce a further group able to 
establish additional hydrogen bonds within the channel. However, piperazine 
derivative 42a was three times less active than spiropiperidine 33 or 
amantadine. Moreover, N-methylation of 42a to 42b and 42c further reduced 
the activity, probably by hampering the hydrogen bonding ability of the 
ligand, 42c being inactive against influenza A/HongKong/68 (H3N2). No 
significant antiviral effect was observed against the amantadine resistant 
influenza A/WSN/33 (H1N1) strain. Notwithstanding the introduction of a 
second nitrogen atom was negative in this spiroadamantanes, other series of 
adamantane derivatives increased their potency with the introduction of a 
second amino group, as we have already seen in section 2. 
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Figure 17. Spiropiperidine 33 and analogs featuring an additional heteroatom. 
 
 Finally, it should be noted that, recently, Kolocouris and coworkers have 
reported the binding constants of some spiroadamantanes against the M2 
channel of the influenza A/chicken/Germany/27 (H7N7, Weybridge strain), 
expressed in E. coli [36]. The binding affinity of spiropiperidine 33 was in the 
submicrolar range (Kd = 0.39 μM), very similar to that of amantadine (Kd = 
0.32 μM), although much higher than that of rimantadine (Kd = 0.016 μM). 
Spiropirrolidines 32a, 32b, and 37b displayed binding affinities in the 
micromolar range (1.16, 2.93, and 1.5 μM, respectively).  
 Unfortunately, sometimes it is difficult to compare the anti-viral activity 
of the different adamantane derivatives. This is, at least partly, a reflection of 
the time-span lasting more than four decades in which these compounds were 
synthesized and tested. For example, while spiropiperidines 30, published in 
1972 [40d], and 33a-c, published in 1996 [42b], were tested against the 
influenza A2/Japan, an H2N2 strain, 41a-b, described in 2007 [44], were 
tested against the influenza A/HongKong/7/87, an H3N2 strain. As the 
activity of amantadine against these strains is different, it is difficult a 
quantitative comparison between the activity of all these compounds. 
Moreover, sometimes the description of the antiviral potency is not very 
accurate. For example, van Hes and coworkers, in describing the antiviral 
activity of 30, only reported “activity comparable to that of amantadine or 
better” without stating a value for the IC50 [40d]. 
 In order to investigate the SAR for their compounds, Kolocouris and 
coworkers have reported a conformational analysis study by a combination of 
NMR spectroscopy and theoretical calculations. They found that, in general, 
for the most active compounds the amine nitrogen atom lies in a distance of 
1.5 to 2.5 Å away from the 2-adamantyl carbon [47]. 
 
5. Aminospiroadamantanes 
 
 As part of its monumental work in adamantane chemistry, Kolocouris’ 
group has also reported the synthesis of several aminospiroadamantanes such 
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as those shown in Fig. 18. These compounds retain the pharmacophore group 
of rimantadine in the C-2 position of the adamantane ring. Compounds 43b 
and 44a showed to be more than 100 times more active than amantadine when 
tested against the influenza A2/Japan/305/57 (H2N2) strain [42a] with SI of 83 
and 24, respectively. 
 
 
 
Figure 18. Aminospiroadamantanes 43 and 44. 
 
 Analogs of 43 featuring a cyclobutyl or cyclopentyl ring have also been 
synthesized and tested against A2/Japan/305/57 (H2N2) and X-31 (H3N2, 
with S31N in the M2 protein) strains [38]. Cyclobutyl derivatives 45 had 
similar potency against the H3N2 strain than rimantadine. Ring enlargement 
resulted in spirocyclopentane analogs 46 which were less potent than their 
cyclobutane analogs. When tested against the X-31 strain, all the new 
compounds showed to be less potent than rimantadine (Fig. 19). 
 Overall, in going from cyclopropyl analogs 43 to cyclopentyl 
derivatives 46, it appears as if increasing the carbon crowding around the 
spiro carbon leads to compounds with reduced antiviral potency. However, 
it must be taken into account that Philips-Duphar researchers reported, in the 
1970s, that the cyclopentyl derivative 47 had, against the A2/Japan/305/57 
(H2N2) strain, an antiviral activity of the same order of DU 34796, that, as 
we have already stated, entered clinical trials [40d]. Moreover, very 
recently, DeGrado’s group disclosed in a patent the structure of the 
cyclohexyl derivative 48, somehow related to spiropiperidine 41a. 
Compound 48, when tested against the wt M2 channel of influenza A virus 
expressed in oocytes of Xenopus laevis, showed an IC50 of 18.7 μM, very 
similar to that of amantadine (IC50 = 16 μM) and was slightly less active 
than rimantadine (IC50 = 10.8 μM). As rimantadine, 48 was inactive against 
the mutant S31N. However, compound 48 revealed to be a submicromolar 
inhibitor of the clinically important mutant V27A (IC50 = 0.31 μM) and also 
showed to be active against the mutant L26F (IC50 = 5.6 μM). To the best of 
our knowledge, 48 is the most potent compound ever reported against the 
mutant V27A [48]. Unfortunately, there is no data regarding the activity of 
compounds 43-47 against the V27A mutant M2 channel. Worthy of note, 
analog 49 has not been synthesized yet. 
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Figure 19. Aminospiroadamantanes 45-48 and unkown compound 49. a, R = H; b,            
R = methyl. 
 
 Taken together the antiviral acitivity of compounds 43 to 48, it seems that 
the distance and orientation between the nitrogen atom and the adamantyl 
cage is more important than the steric hindrance around the spiro carbon atom. 
 
6. 1,2-Annulated adamantane derivatives 
 
 In the earlier 1970s, several patents by Squibb claimed anti-influenza 
activity for a series of 1,2-annulated adamantanopyrrolidines of general 
structure 50 (Fig. 20), although no much details regarding biological activity 
were given [49]. Nearly forty years later, Kolocouris’s group synthesized 
several adamantanopyrrolidines 51-52, the related compound 53 and  1,2-
annulated adamantanopiperidines of general structures 54-56 and tested them 
against influenza A/Hong Kong/7/87 (H3N2) strain [50]. 
 
 
 
Figure 20. 1,2-Annulated adamantane derivatives 50-56. a, R = H; b, R = methyl; c,        
R = ethyl. 
 
 The compounds 52a and 56a elicited submicromolar activities (IC50 of 0.5 
and 0.6 μM, respectively) and a SI of 732 and 200, respectively, being 
equipotent to rimantadine (IC50 = 0.36 μM). Compounds 51 and 54, with the 
nitrogen atom attached directly to the C-2 position of the adamantane ring, 
showed low micromolar activities (between 2 and 8 μM), similar to that of 
amantadine (2.0 μM). 
 As previously seen in other series, these results showed that a large 
lipophilic moiety in the vicinity of adamantane skeleton is compatible with 
good anti-viral activity, that moving the amine nitrogen atom away from the 
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2-adamantyl carbon atom enhaces activity (compare 52a, IC50 = 0.6 μM, with 
51a, IC50 = 2.2 μM), and that N-alkylation reduced the potency (compare 52a, 
IC50 = 0.5 μM, with 52c, IC50 = 2.4 μM, or 56a, IC50 = 0.6 μM, with 56b,  
IC50 > 500 μM). 
 In closing sections 2 to 5, it should be mentioned that in 2009, K.-C. Chou 
published a fragment-based quantitative structure-activity relationship              
(FB-QSAR) study with 34 substituted adamantanes. His main conclusion was 
that position 2 of the adamantane was more sensitive to substitution than 
position 1 [51]. 
 
7. 2-Azaadamantanes and (2-oxaadamant-1-yl)amines 
 
 Geigy has claimed that 2-azaadamantane, 57 (Fig. 21), first described in 
1964 by Stetter et al. [52], displayed antiviral activity against three different 
influenza A H2N2 strains: A/Bethesda/10/63, A/Taiwan/1/62 and 
A/Singapore/1/57, but not further progress was published later [53]. 
 More recently, we have found that replacement of the methylene unit of 
C-2 in amantadine by an oxygen atom to obtain (2-oxaadamant-1-yl)amine, 
58, reduced the antiviral activity [54]. 
 
 
 
Figure 21. 2-azaadamantane and (2-oxaadamant-1-yl)amines. 
 
8. BL-1743 and related compounds 
 
 In 1995, Bristol-Myers Squibb’s researchers carried out a high-throughput 
screen based on the ability of inhibitors to reverse the toxicity associated with 
M2 channels expressed in the yeast Saccharomyces cerevisiae membranes. 
They found an azaspiro[5.5]undecane derivative, BL-1743, able to efficiently 
inhibit the activity of wt influenza A M2 channels (Fig. 22) [55]. The 
mechanism of action of BL-1743 was further characterized by 
electrophysiological methods. BL-1743 was also able to inhibit the AM2 
channel expressed in Xenopus oocytes, as determined using the two-electrode 
voltage clamp (TEV) technique. It was found that the majority of M2 
sequences isolated from influenza viruses resistant to amantadine were also 
resistant to BL-1743, which suggests that BL-1743 binds competitively with 
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amantadine. Interestingly, the kinetics of channel inhibition by BL-1743 were 
more rapid, showing a fast onset of inhibition as well as a reasonably rapid 
reversal of inhibition following removal of the compound [56]. This behavior 
contrasts with that of amantadine, whose second-order rate constant for the 
onset of inhibition is much slower than the diffusion-controlled rate, and 
whose off-rate is essentially irreversible on the minute to hour time scale of 
the experiment. The Hill coefficient for inhibition was 1.0, which is consistent 
with the binding ratio of one BL-1743 per AM2 tetramer [56]. 
 It should be noted that twenty years before the discovery of BL-1743, A. 
H. Robins Company Inc., in a US patent [57], claimed anti-influenza activity 
for a series of aminospiranes that were already known from older literature 
[58]. Compounds 59-61 (Fig. 22) protected chicken embryos against influenza 
A/Taiwan/1/64 (H2N2) strain better or similarly than amantadine. No 
information about the activity of these compounds against amantadine-
resistant strains was disclosed. 
 
 
 
Figure 22. BL-1743 and related aminospiro[5.5]undecanes. 
 
 Taking into account the recent determination of the 3-D structure of the 
M2 ion channel of influenza A virus [19], and the structural difference 
between BL-1743 and the amantadine class of compounds, in 2008 Pinto’s 
and DeGrado’s groups started a SAR study of this scaffold with the aim of 
discovering new inhibitors of amantadine-resistant mutants [59]. 
 Interestingly, spiropiperidine 62a (Fig. 23), an analog of BL-1743 lacking 
the imidazoline group, had an IC50 of 0.9 μM against the influenza A wt M2 
channel expressed in the Xenopus oocytes membrane, which is more than one 
order of magnitude more potent than amantadine (IC50 = 16 μM) and represents 
a more than 45-fold increase in potency relative to BL-1743 (IC50 = 45.3 μM). 
Alkylation of 62a with a methyl group to 62b reduced the potency (IC50 = 20.6 
μM), and alkylation with larger groups as in 62c led to inactive compounds. 
Several N-heteroarylmethyl derivatives of 62 were also inactive. Worthy of 
note, solid-state NMR data indicated that 62a interacts with influenza A M2 
channel differently from amantadine, affecting a longer stretch of the 
transmembrane helix and immobilizing the G34-I35 region. Ring-contracted 
analogs 63 and 64 were also active (IC50 = 8.1 and 12.0 μM, respectively) 
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although were less potent than 62a. Dithiene 65 was moderately active           
(IC50 = 37.6 μM), while ketal 66 was inactive [59a]. Finally, it should be noted 
that 62a can be seen as a simplified analog of Kolocouris’ spiroadamantane 41a 
(Figure 16), a compound that, when tested against influenza A/Hong Kong/7/87 
(H3N2) strain, was found to be 12-fold more active than amantadine [44]. 
 
 
 
Figure 23. Spiropiperidine 62 and related compounds. a, R = H; b, R = methyl; c,               
R = methylcyclopropyl; d, R = methyl-2-pyridyl; e, R = methyl-2-imidazolyl. 
 
 Moving the nitrogen atom out of the spiro-ring led to the aforementioned 
amine 59. DeGrado’s group found that 59 had an IC50 of 12.6 μM, very 
similar to amantadine. Analogs 67 and 68 were also active (IC50 = 15.7 and 
14.6 μM, respectively), while more complex derivatives, such as 69 were 
inactive (Fig. 24) [59b]. Interestingly, while 59 was less potent than 62a 
against the wt channel of influenza A, 59 was active against the amantadine-
resistant L26F and V27A mutants (IC50 = 30.6 and 84.9 μM, respectively) and 
also inhibited replication of recombinant mutant viruses bearing these 
mutations in plaque reduction assays. However, 59 was inactive against the 
S31N mutant. It is interesting to compare the structure and the activity of 59 
with the spiroadamantane 48 (Fig. 19). While 59 and 48 displayed very 
similar activities against the wt channel (IC50 = 12.6 and 18.7 μM, 
respectively), 48 is much more potent against the amantadine-resistant 
mutants (V27A, IC50 = 0.3 μM; L26F, IC50 = 5.6 μM) [48]. 
 
 
 
Figure 24. Spiro[5.5]undecan-3-amine 59 and related compounds. 
 
9. Ring-contracted adamantane analogs 
 
 For the wt M2 protein, the diameter of the hole made from four Ser31 of 
separate trans-membrane chains is about 8 Å. However, after the mutation of 
residue 31 from Ser to Asn, the diameter of this hole was reduced to 6.32 Å 
[20i]. As the X-ray structure of the M2-amantadine complex shows that 
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amantadine is located in the hole between Ser31 and Ala34, the mutation of 
Ser to Asn leaves less space for amantadine entering or being stabilized [19d]. 
 Taking into account this reduction in the space available for binding, we 
synthesized a series of ring-contracted amantadine and rimantadine analogs, 
featuring noradamantane and bisnoradamantane scaffolds (Fig. 25). Several 
derivatives showed low micromolar inhibitory activities of the wt M2 channel 
ranging from IC50 = 2.4 μM for guanidine 72 to IC50 = 17 μM for 71 and 75. 
The activity was confirmed by plaque reduction assays with influenza 
A/Udorn/72 (H3N2) strain, carrying wt M2 protein and, for 70 it was also 
confirmed in an assay of inhibitory effect on virus replication using influenza 
A/Hong Kong/7/87 (H3N2) strain [60]. However, only bisnoradamantane 
derivative 74 showed to be moderately active against the S31N channel                
(IC50 = 252 μM), being less potent than amantadine (IC50 = 200 μM) [60b]. 
Several bisnoradamantanes carrying additional rings were also studied and some 
of them showed to be slightly less potent than amantadine. For example, 
pyrrolidine derivative 76, had IC50 = 24 μM against the wt channel of influenza A.  
 
 
 
Figure 25. Ring-contracted analogs of amantadine and rimantadine. 
 
 Cubylamines also can be regarded as ring-contracted analogs of amantadine 
and rimantadine. In 1971, Du Pont de Nemours, claimed in a patent anti-
influenza activity for several cubane derivatives, such as 4-methylcubane-1-
amine, 77, and α,4-dimethylcubane-1-methylamine, 78 (Fig. 25). When mice 
infected with the influenza A/Ann Arbor/2/60 (H2N2) strain were treated with 
the rimantadine analog 78, there was a 70% survival rate as compared with 20% 
survivors in the infected, non-treated control animals [61]. 
 
10. Aminobicyclo[2.2.1]heptanes, aminobicyclo[2.2.2]octanes and 
related compounds 
 
 As early as in 1969, Smith Kline & French disclosed that 
bicyclo[2.2.1]heptanes 79-81 (Fig. 26) had anti-influenza activity. They 
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reported that compound 80, at oral and subcutaneous doses of 25-100 mg/kg, 
caused a 35-80% and a 30-75% increase in survival of mice infected with the 
influenza A/Ann Arbor/2/60 (H2N2) strain, and with a swine strain of 
influenza A, respectively [62]. Although no further details have been 
published in the western literature related to the antiviral activity of 79 or 80, 
later, Russian researchers found that an isomeric mixture of 81 and 82 
effectively inhibited replication of influenza viruses and this mixture, as its 
hydrochloride, known as deitiforin, has been in used as antiviral in the former 
USSR for several years [63]. As an anti-influenza drug, deitiforin is equal to 
rimantadine from the standpoint of the protective effect in the treatment of 
influenza infection, and it can not only efficiently supress virus-specific 
growth, but can also selectively act on virus-infected cells. It has been found 
that influenza A/Victoria/35/72 (H3N2) strain resistant to deitiforin  mutated 
the M2 protein in 3 amino acids: Met14Leu, Ala30Val and Met59Leu [64]. 
Interestingly, compound ICI 130685, which can be regarded as a derivative of 
81 with further rings, advanced into clinical trials, but was not approved for 
clinical use [65]. 
 García Martínez and coworkers have reported that several                     
1-norbornylamines were also endowed with potent anti-influenza activity. 
Secondary amines 83 and 84 were more potent than amantadine and showed 
very high SI [66]. 
 
 
  
Figure 26. Bicyclo[2.2.1]heptanes with anti-influenza activity. 
 
 In 1969, DuPont de Nemours & Co, also claimed anti-influenza activity 
for a series of bicyclo[2.2.2]octan-1-amines, 85, bicyclo[2.2.2]oct-2-en-1-
amines, 86, bicyclo[2.2.2]octane-1-methylamines, 87, and bicyclo[2.2.2]oct-
2-ene-1-methylamines, 88 [67]. They tested the compounds in mice using the 
influenza A/swine/S-15 strain and found that the unsaturated cage amines 
were similar in antiviral activity to their saturated counterparts. As seen in 
other families of polycyclic amines, substitution on the amino group with 
alkyl groups decreased the anti-viral activity. The addition of a methyl group 
in C-4 of the bicyclo[2.2.2]octane was optimal but inclusion of a larger group 
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reduced the activity. Finally, the presence of α-alkyl groups in the 
bicyclo[2.2.2]octane-1-methylamine series enhances antiviral activity. 
Overall, rimantadine analog 89 was the most active compound. 
 
87 88 8985 86
NR1R2
R3
NR1R2
R3
R3 R3
NR1R2 NR1R2 NH2
 
 
Figure 27. Bicyclo[2.2.2]octan-1-amine, 85, and related compounds. 
 
 Interestingly, Inamoto and co-workers reported the synthesis of several 
tricyclo[5.3.1.03,8]undecane (4-homoisotwistane) derivatives, such as amines 
90 and 91. 4-Homoisotwistanes can be seen as bicyclo[2.2.2]octane 
derivatives carrying an additional ring. Amines 90 and 91 were quite active 
against the Newcastle disease virus, which is sensitive to amantadine and is 
the causal agent of a bird disease that, when infecting humans, causes 
influenza-like symptoms. However, they did not test these compounds against 
influenza virus [68]. 
 
 
 
Figure 28. Tricyclo[5.3.1.03,8]undecane derivatives. 
 
11. Other polycycloalkanes with anti-influenza activity 
 
 Finally, in this section we will discuss several unrelated polycyclic 
structures that have shown anti-influenza activity. For example, there are 
several amines derived from the pentacyclo[5.4.0.02,6.03,10.05,9]undecane that 
have been biologically tested. In the 1970s, Smith, Kline & French, reported 
that amine 92 (Fig. 29) showed marginal activity against influenza A/Ann 
Arbor, while its isomer 93 was inactive [69]. Very recently, DeGrado and 
coworkers have found that amine 94 inhibited the activity of the wt M2 
channel of influenza A expressed in oocytes of Xenopus laevis, with an           
IC50 = 8 μM, lower than that of amantadine (IC50 = 16 μM) and rimantadine 
(IC50 = 10.8 μM). As seen in other polycyclic derivatives, the addition of a 
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hydroxyl group, as in 95, was compatible with inhibitory activity (IC50 = 24 μM), 
but not increased the potency [30]. 
 
 
 
Figure 29. Derivatives of pentacyclo[5.4.0.02,6.03,10.05,9]undecane. 
 
 In 2010, Hu et al. carried out the screening of a small primary amine 
library as M2 protein inhibitors. They reported that linear alkyl amines, 
aromatic amines and unsubstituted monocyclic amines were inactive. 
However, they found five compounds, 14, previously studied by Scholtissek 
[33], and 96-99 (Fig. 30), with similar activities to that of amantadine. 
Isopinocamphenylamine 99, the most potent inhibitor, was three times more 
active than amantadine (IC50 = 1.4 μM vs IC50 = 6.0 μM) for viral inhibition 
of the influenza A/Hong Kong/8/68 (H3N2) strain [70]. Encouraged by these 
results, the same group has very recently published a small library of 
derivatives of 99 obtained by keeping the scaffold constant and modifying the 
amino functionality. The compounds were evaluated for viral inhibiton against 
influenza A/WS/33 (H1N1), amantadine resistant, and influenza A/Hong 
Kong/8/68 (H3N2), amantadine sensitive. Although there was no inhibition of 
the amantadine resistant strain, most of the compounds exhibited antiviral 
inhibition as good as amantadine against the amantadine sensitive strain. 
Compound 100 (IC50 = 0.09 μM) was nearly 240-fold more potent than 
amantadine against wt influenza A virus [71]. 
 
 
 
Figure 30. Primary amine inhibitors of M2 channel and derivative 100. 
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 Finally, DeGrado and coworkers tested the inhibitory activity against wt 
M2 channel of a series of branched and polycyclic amines (Fig. 21) [30]. 
Surprisingly, branched alkyl amine 101 was nearly as active as amantadine 
(IC50 = 21 μM vs IC50 = 16 μM), tricyclic amine 102, showed higher activity 
than amantadine (IC50 = 9 μM) and four homoadamantane derivatives,           
103-105 and 13 showed similar activity as amantadine, suggesting that the 
M2 channel can accommodate a wide range of structural diversity and               
that is insensitive to minor scaffold modifications, so long as the shape of 
the molecule conforms to the M2 cavity. All these compounds were found    
to be less potent or inactive against V27A and/or S31N mutant               
channels, probably as a consequence of the higher polarity of the mutant 
channels [30]. 
  
 
 
Figure 31. Several inhibitors of M2 channel. 
 
12. Conclusion 
 
 Although amantadine and rimantadine have been in clinical use for 
many years and hundreds of analogs have been tested as anti-influenza 
agents, the results obtained so far are a bit disappointing. While several 
active compounds have been found, occasionally having more potency than 
amantadine and rimantadine, cross-resistance with both drugs is still an 
unresolved issue. The above notwithstanding, the recent structural, 
functional, and computational studies carried out with M2 protein have 
opened the door to the rational design of new inhibitors [72], and, very 
recently, some derivatives have shown promising activity against the V27A 
amantadine-resistant mutant [30,48,59]. The S31N mutant is still even a 
major challenge. 
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